Edition:
United Kingdom

Adaptimmune Therapeutics PLC (ADAP.OQ)

ADAP.OQ on NASDAQ Stock Exchange Global Select Market

8.62USD
16 Feb 2018
Change (% chg)

$0.11 (+1.29%)
Prev Close
$8.51
Open
$8.54
Day's High
$8.79
Day's Low
$8.35
Volume
80,138
Avg. Vol
83,513
52-wk High
$9.70
52-wk Low
$3.88

Chart for

About

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR,... (more)

Overall

Beta: --
Market Cap(Mil.): $763.12
Shares Outstanding(Mil.): 93.52
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.64
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Adaptimmune Therapeutics Says On Jan 5, Co Entered Into Agreement With Cell, Gene Therapy Catapult For Vector Production In UK

* ADAPTIMMUNE THERAPEUTICS SAYS ON JAN 5, CO ENTERED INTO AGREEMENT WITH CELL AND GENE THERAPY CATAPULT FOR VECTOR PRODUCTION IN UK - SEC FILING

08 Jan 2018

BRIEF-Adaptimmune Announces Positive Safety Data From Pilot Studies With MAGE-A10 SPEAR T-Cells

* ADAPTIMMUNE ANNOUNCES POSITIVE SAFETY DATA FROM PILOT STUDIES WITH MAGE-A10 SPEAR T-CELLS AND FIRST PATIENT TO RECEIVE 1 BILLION TARGET CELL DOSE

08 Jan 2018

BRIEF-Adaptimmune Therapeutics Q3 loss per share $0.00

* Adaptimmune reports third quarter 2017 financial results and business updates

02 Nov 2017

BRIEF-Matrix Capital reports 12.9 pct passive stake in Adaptimmune Therapeutics

* Matrix Capital Management Company Lp reports 12.9 percent passive stake in Adaptimmune Therapeutics Plc as of August 31, 2017 - SEC filing Source text: (http://bit.ly/2wSEc1U)

11 Sep 2017

GSK bets on pioneering cancer therapy with Adaptimmune deal

LONDON GlaxoSmithKline said it has licensed the rights to Adaptimmune's pioneering T-cell therapy program to boost its pipeline in oncology, one of four areas its has prioritized for research and development.

07 Sep 2017

GSK bets on pioneering cancer therapy with Adaptimmune deal

LONDON, Sept 7 GlaxoSmithKline said it has licensed the rights to Adaptimmune's pioneering T-cell therapy programme to boost its pipeline in oncology, one of four areas its has prioritised for research and development.

07 Sep 2017

BRIEF-GSK exercises option over SPEAR T-cell therapy program targeting NY-ESO

* Adaptimmune Therapeutics Plc - ‍GSK exercises option over SPEAR T-cell therapy program targeting NY-ESO​

07 Sep 2017

Earnings vs. Estimates